Public Source Meta-databases — Our Approach
Pharsight’s collection of therapeutic area and indication-focused databases have been compiled with a deliberate focus to enable knowledge build-out and enhanced client deliverables for decision-making.
Public data sources on competitors and analogues from the clinical and scientific literature, collectively called “meta-data”, are diverse and include:
- Published journal articles
- Regulatory documents (e.g., FDA Summary Basis for Approval)
- Package inserts or promotional materials from the drug manufacturer
- Published abstracts or poster presentations
- Meeting proceedings
- Web documents (e.g., press releases about new clinical trial results)
- Online clinical trial registries
All data are formatted and entered in a “ready-to-model” meta-database that undergoes multiple quality design and check stages.
Meta-databases provide a publicly available start point for modeling efforts to address specific drug development program questions. Each meta-database has been developed to provide a directed view of the public source information landscape for a given disease state/indication.
Pharsight meta-databases can be leveraged to make modeling results readily available to clinical development teams and to communicate the predictive results of modeled product profiles using visualization software tools, such as Pharsight Drug Model Explorer® (DMX®).